The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy

BACKGROUND: The gut microbiome is implicated as a marker of response to  immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early studies suggest faecal microbial transfer may have therapeutic potential, convertin...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Nicola A., Stewart, Grant D., Welsh, Sarah J., Doherty, Gary J., Robinson, Matthew J., Neville, B. Anne, Vervier, Kevin, Harris, Simon R., Adams, David J., Dalchau, Katy, Bruce, David, Demiris, Nikolaos, Lawley, Trevor D., Corrie, Pippa G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785032/
https://www.ncbi.nlm.nih.gov/pubmed/35073853
http://dx.doi.org/10.1186/s12885-021-09156-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8785032/
https://www.ncbi.nlm.nih.gov/pubmed/35073853
http://dx.doi.org/10.1186/s12885-021-09156-x

Ejemplares similares